Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenues
Operating Expenses:    
Research and development 777 1,650
Selling, general and administrative  (including $102 and $718 from stock compensation granted to officers, directors and employees during the three months ended March 31, 2024 and 2023, respectively) 2,314 2,015
Loss from Operations 3,091 3,665
Other (Income) Expense    
Interest income (142) (164)
Interest expense 212
Change in fair value of warrant liability (658) (2,924)
Gain on extinguishment of debt (533)
Unrealized loss (gain) on marketable securities 2 (29)
Other (27)
Total Other (Income) Expense (825) (3,438)
Net Loss $ (2,266) $ (227)
Net Loss Per Share - Basic $ (1.64) $ (0.21)
Net Loss Per Share - Diluted $ (1.64) $ (0.21)
Weighted average common shares outstanding - basic 1,380,633 1,082,871
Weighted average common shares outstanding - diluted 1,380,633 1,082,871